The Technical Analyst
Recursion [RXRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Recursion Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.96% $8.68
America/New_York / 7 mai 2024 @ 12:46
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 996.18 mill |
| EPS: | -1.600 |
| P/E: | -5.42 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 230.11 mill |
| Avg Daily Volume: | 6.48 mill |
| RATING 2024-05-07 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.42 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.92x |
| Company: PE -5.42 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 8.03 - 9.35 ( +/- 7.55%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-05-02 | Gibson Christopher | Sell | 21 296 | Class B Common Stock |
| 2024-05-01 | Gibson Christopher | Sell | 25 000 | Class A Common Stock |
| 2024-05-01 | Gibson Christopher | Sell | 50 000 | Class A Common Stock |
| 2024-05-02 | Gibson Christopher | Buy | 21 296 | Class A Common Stock |
| 2024-05-02 | Gibson Christopher | Sell | 21 296 | Class A Common Stock |
| INSIDER POWER |
|---|
| 38.38 |
| Last 99 transactions |
| Buy: 2 817 271 | Sell: 1 191 870 |
Forecast:
14:26 - $8.68
Live Trading Signals (every 1 min)
Forecast
1: 12:56 - $8.68
Forecast 2: 13:46 - $8.69
Forecast 3: 14:26 - $8.68
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.68 (-2.96% ) |
| Volume | 1.867 mill |
| Avg. Vol. | 6.48 mill |
| % of Avg. Vol | 28.83 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RXRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $10.01 | N/A | Active |
|---|
RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Latest Press Releases
2024-05-02 08:00:00 - Press Release
Recursion To Report First Quarter 2024 Business Updates And Financial Results On May 9
Salt lake city, may 02, 2024 (globe newswire) -- recursion (nasdaq: rxrx), a leading clinical stage techbio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its first quarter 2024 financial results on thursday, may 9, 2024, following the close of the financial markets. additionally, recursion will host its quarterly l(earnings) call on may 9, 2024 at 5:00 pm eastern time / 3:00 pm mountain time.
2024-05-01 08:01:00 - Press Release
Recursion To Participate In Upcoming Investor Conferences
Salt lake city, may 01, 2024 (globe newswire) -- recursion (nasdaq: rxrx), a leading clinical stage techbio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences:
2024-04-16 08:00:00 - Press Release
Recursion Appoints Najat Khan, Phd, As Chief R&d Officer And Chief Commercial Officer
Dr. khan, formerly the chief data science officer and global head of strategy and portfolio, innovative medicine r&d at johnson & johnson (j&j), will also join recursion's board of directors dr. khan, formerly the chief data science officer and global head of strategy and portfolio, innovative medicine r&d at johnson & johnson (j&j), will also join recursion's board of directors
2024-03-26 08:00:00 - Press Release
Recursion Publishes Annual Environmental, Social And Governance Report
Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact. provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact.
2024-03-11 04:00:00 - Press Release
Recursion Announces Plans To Open New Office In London
Appoints michael bronstein as scientific advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class techbio talent in the heart of king's cross neighborhood appoints michael bronstein as scientific advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class techbio talent in the heart of king's cross neighborhood
Latest News
2024-05-03 18:56:15 - Zacks Investment Research
Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $8.84, denoting a +0.57% change from the preceding trading day.
2024-05-02 10:01:14 - Zacks Investment Research
Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Recursion Pharmaceuticals (RXRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
2024-05-01 08:01:00 - GlobeNewsWire
Recursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences:
2024-04-27 07:00:00 - InvestorPlace
The Top 3 Biotech Stocks to Buy in April 2024
Biotech stocks are notorious for being some of the most volatile and unpredictable on the market. With clinical trials and FDA approvals creating potential leaps or falls in what seems like an instant, there is no denying the risk involved.
2024-04-25 18:56:26 - Zacks Investment Research
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Recursion Pharmaceuticals (RXRX) closed at $7.84 in the latest trading session, marking a -1.26% move from the prior day.
2024-04-15 12:54:18 - InvestorPlace
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.
2024-04-10 05:50:00 - The Motley Fool
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good.
2024-04-04 08:45:00 - The Motley Fool
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?
Recursion Pharmaceuticals' approach to developing drugs is ambitious. But the company has yet to produce the kinds of results investors want.
2024-04-03 10:36:06 - Zacks Investment Research
Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround
Recursion Pharmaceuticals (RXRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2024-04-01 13:00:38 - Zacks Investment Research
All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to Buy
Recursion Pharmaceuticals (RXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).